Results of studies employing animal models and patients with MASLD suggest that alterations of intestinal barrier function and an increased translocation of bacterial endotoxin but also other PAMPs are critical in the development of MASLD and the induction of hepatic TNFα expression (for overview see [48]). The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.